CRLF2/JAK2 mutant B-ALL cells that remained viable following long-term depletion or pharmacological inhibition of JAK2 developed an adaptive response that featured enhanced expression of c-Myc and downstream Myc target genes. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.